It was reported by Zacks that sales of the present fiscal quarter of $2.62 Million will be announced by the Infinity Pharmaceuticals as per the forecast of the Wall Street brokerages. Estimates have been provided by two analysts for the earnings of the Infinity Pharmaceuticals. $5 Million is the highest prediction of the sales whereas the lowest amount of sales expected is $240K. It has been anticipated that the business will be issuing its report for next earnings of the quarter on the 6th of August.
On an average, the analysts are anticipating that the Pharmaceuticals Company will be reporting for the sales of a complete year of $6.79M for the present fiscal year, with predictions which range from $1.36M to $17 Million. For the coming year, the analysts have predicted that Infinity Pharmaceuticals Inc. will be reporting the sales of $2.94M. The calculations of Zack’s sales are an average based on a conducted survey of the analyst who is following the Specialty Pharmaceuticals Company.
Results of the last earnings of the Infinity Pharmaceuticals Inc. were posted on the 7th of May, which was Tuesday. For the quarter $0.24 earnings per share, as well as, the consensus prediction of $0.05/0.19of the missing analysts were reported by the Pharma Company. The total revenue of the business earned during the quarter was of $2.14 Million as compared to the predictions of the analysts of $10.01 million.
A various number of analysts passed comments on the shares of the Infinity Pharmaceuticals Inc. recently. Zacks Investment Research lifted the Infinity Pharmaceuticals to a buy rating from the hold rating. The target price on the stock was set on $2 on the 8th of April. ValueEngine also reportedly lifted the Specialty Pharma Company from sell to hold rating.